

Paolo Pedrazzoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6902580/publications.pdf>

Version: 2024-02-01

281
papers

6,199
citations

81900

39
h-index

98798

67
g-index

294
all docs

294
docs citations

294
times ranked

7591
citing authors

#	ARTICLE	IF	CITATIONS
1	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	7.1	50
2	Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up. <i>ESMO Open</i> , 2022, 7, 100359.	4.5	14
3	Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 338-338.	1.6	2
4	Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study. <i>ESMO Open</i> , 2022, 7, 100458.	4.5	18
5	Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2022, 14, 389-393.	2.0	5
6	Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?. <i>Nutrition</i> , 2022, 98, 111637.	2.4	5
7	Muscle weakness as an additional criterion for grading sarcopenia-related prognosis in patients with cancer. <i>Cancer Medicine</i> , 2022, 11, 308-316.	2.8	6
8	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	2.8	11
9	A Nutritional Approach for the Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer. <i>Nutrients</i> , 2022, 14, 1801.	4.1	5
10	Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 679.	2.5	2
11	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	2.4	119
12	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	2.8	19
13	Infectious complications and immunotherapy: old pitfalls and new horizons. <i>Future Oncology</i> , 2022, 18, 2377-2381.	2.4	8
14	Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA. <i>Supportive Care in Cancer</i> , 2022, 30, 7645-7653.	2.2	1
15	Humoral and cell-mediated immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with cancer on active treatment: Focus on wild type, Delta and Omicron strains.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13505-e13505.	1.6	0
16	Clinical effectiveness of SARS-CoV-2 vaccines and booster doses in patients with cancer: An analysis from the European OnCovid registry.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18725-e18725.	1.6	0
17	Management of Nutritional Needs in Pediatric Oncology: A Consensus Statement. <i>Cancers</i> , 2022, 14, 3378.	3.7	22
18	Clinical and economic value of oral nutrition supplements in patients with cancer: a position paper from the Survivorship Care and Nutritional Support Working Group of Alliance Against Cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 9667-9679.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Store-Operated Ca ²⁺ Entry Is Up-Regulated in Tumour-Infiltrating Lymphocytes from Metastatic Colorectal Cancer Patients. <i>Cancers</i> , 2022, 14, 3312.	3.7	7
20	Validation of a new prognostic body composition parameter in cancer patients. <i>Clinical Nutrition</i> , 2021, 40, 615-623.	5.0	13
21	Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas. <i>Annals of Surgical Oncology</i> , 2021, 28, 1167-1177.	1.5	19
22	7. The Human-Digital Twin in the manufacturing industry: current perspectives and a glimpse of future. , 2021, , .		4
23	The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: study protocol of a randomized, open-label, parallel group, bicentric pilot study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110258.	3.2	5
24	Nutrition in Survivorship Care. , 2021, , 371-377.		1
25	Serum tumour markers in germ cell tumours: From diagnosis to cure. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103224.	4.4	15
26	Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches. <i>Cancers</i> , 2021, 13, 1577.	3.7	5
27	Immunonutrition in head and neck cancer patients undergoing chemoradiotherapy: an alternative approach for overcoming potential bias. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1053-1054.	4.7	2
28	Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons?. <i>Future Oncology</i> , 2021, 17, 1577-1580.	2.4	5
29	Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need. <i>Current Oncology Reports</i> , 2021, 23, 84.	4.0	5
30	Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlufusp I± in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/metastatic renal cell carcinoma (RCC) (NCT03063762).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4556-4556.	1.6	5
31	Breast Cancer and HIV: State of the Art and Practical Implications. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1727-1739.	0.6	1
32	Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 35.	1.5	11
33	The prognostic impact of BIA-derived fat-free mass index in patients with cancer. <i>Clinical Nutrition</i> , 2021, 40, 3901-3907.	5.0	16
34	Influence of different lipid emulsions on specific immune cell functions in head and neck cancer patients receiving supplemental parenteral nutrition: An exploratory analysis. <i>Nutrition</i> , 2021, 86, 111178.	2.4	9
35	Reply to Y. Ergun et al. <i>JCO Oncology Practice</i> , 2021, 17, 457-457.	2.9	3
36	G-CSF and G-CSF-related vasculitis: a systematic review of the literature and intriguing future research perspectives. <i>Future Oncology</i> , 2021, 17, 4619-4634.	2.4	5

#	ARTICLE	IF	CITATIONS
37	Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma. <i>Drugs in Context</i> , 2021, 10, 1-6.	2.2	1
38	Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer. <i>Journal of Functional Foods</i> , 2021, 83, 104533.	3.4	8
39	1009P Current strategies of cell and gene therapy for solid tumors: Preliminary results of the joint international ESMO and EBMT Cell Therapy and Immunobiology Working Party questionnaire-based survey. <i>Annals of Oncology</i> , 2021, 32, S852.	1.2	0
40	1676P Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients. <i>Annals of Oncology</i> , 2021, 32, S1177.	1.2	0
41	Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research. <i>Immunotherapy</i> , 2021, 13, 1369-1372.	2.0	6
42	925TiP The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: Study protocol of a randomized, open-label, parallel group, bicentric pilot study. <i>Annals of Oncology</i> , 2021, 32, S814.	1.2	0
43	A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. <i>ESMO Open</i> , 2021, 6, 100272.	4.5	34
44	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2021, 22, 1438-1447.	10.7	45
45	The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. <i>Microvascular Research</i> , 2021, 138, 104189.	2.5	11
46	Nutritional care in cancer patients: Initiatives and perspectives of the Italian Intersociety Working Group for Nutritional Support in Cancer Patients. <i>Nutrition</i> , 2021, 91-92, 111358.	2.4	4
47	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
48	Metastatic Mediastinal Germ Cell Tumor and Concurrent COVID-19: When Chemotherapy Is Not Deferrable. <i>Oncologist</i> , 2021, 26, e347-e349.	3.7	3
49	Smart quality control powered by machine learning algorithms. , 2021, , .		3
50	Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	0
51	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , 2021, 22, 1669-1680.	10.7	73
52	Prognostic nutritional index (pni) in oncogene addicted advanced non-small cell lung cancer (ansclc) patients (pts): an Italian experience. <i>Clinical Nutrition ESPEN</i> , 2021, 46, S711.	1.2	0
53	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	3.2	5
54	THE RESILIENCE OF ONCOLOGISTS DURING THE EARLY TIME OF THE COVID-19 PANDEMIC. , 2021, 01, 56.		0

#	ARTICLE	IF	CITATIONS
55	Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center. <i>European Journal of Surgical Oncology</i> , 2020, 46, 15-23.	1.0	24
56	Nutritional support in cancer patients: reply to Scarpi et al. <i>Supportive Care in Cancer</i> , 2020, 28, 1549-1550.	2.2	1
57	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020, 12, 2948.	3.7	14
58	Hydrogen Sulfide-Evoked Intracellular Ca ²⁺ Signals in Primary Cultures of Metastatic Colorectal Cancer Cells. <i>Cancers</i> , 2020, 12, 3338.	3.7	15
59	Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall. <i>Cancers</i> , 2020, 12, 3441.	3.7	10
60	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3583.	3.7	16
61	Cancer-related malnutrition management: A survey among Italian Oncology Units and Patients' Associations. <i>Current Problems in Cancer</i> , 2020, 44, 100554.	2.0	25
62	How to Use Prophylactic G-CSF in the Time of COVID-19. <i>JCO Oncology Practice</i> , 2020, 16, 771-772.	2.9	12
63	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020, 31, S1078.	1.2	2
64	Reply to: The challenge for nutritional care in a cancer center: The need for integration between clinical nutritionist, oncologist and palliative care physician. <i>Current Problems in Cancer</i> , 2020, 44, 100648.	2.0	0
65	Importance of body composition in grading body mass index and weight loss-related nutritional risk in cancer patients. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 550-551.	1.2	0
66	The need to reappraise the definition of sarcopenia in cancer patients. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 551.	1.2	0
67	The Role of Nutritional Support in Cured/Chronic Patients. <i>Nutrients</i> , 2020, 12, 3167.	4.1	2
68	The Advantages of Clinical Nutrition Use in Oncologic Patients in Italy: Real World Insights. <i>Healthcare (Switzerland)</i> , 2020, 8, 125.	2.0	10
69	Providing nutritional care to cancer patients during the COVID-19 pandemic: an Italian perspective. <i>Supportive Care in Cancer</i> , 2020, 28, 3987-3989.	2.2	11
70	Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	3.2	42
71	Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989028.	3.2	6
72	Monitoring Response to Home Parenteral Nutrition in Adult Cancer Patients. <i>Healthcare (Switzerland)</i> , 2020, 8, 183.	2.0	8

#	ARTICLE	IF	CITATIONS
73	PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. <i>Modern Pathology</i> , 2020, 33, 1398-1409.	5.5	35
74	Nutritional support in pancreatic cancer. <i>Cancer</i> , 2020, 126, 1810-1811.	4.1	8
75	Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report. <i>Nutrition</i> , 2020, 73, 110720.	2.4	2
76	Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9004-9004.	1.6	19
77	Commentary: "My Husband Affects Me More Than My Cancer": Reflections on Simultaneous Intimate Partner Violence and Breast Cancer Experience in a 48-Year-Old Woman'. <i>Journal of Cancer Treatment & Diagnosis</i> , 2020, 4, 36-38.	0.9	0
78	Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. <i>ESMO Open</i> , 2020, 5, e000860.	4.5	1
79	Nutritional Therapy in Cancer Patients Receiving Chemoradiotherapy: Should We Need Stronger Recommendations to Act for Improving Outcomes?. <i>Journal of Cancer</i> , 2019, 10, 4318-4325.	2.5	35
80	Development of adaptive immune effector therapies in solid tumors. <i>Annals of Oncology</i> , 2019, 30, 1740-1750.	1.2	35
81	Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1001-1012.	9.1	25
82	SUN-PO217: Validation of a New Prognostic Body Composition Parameter in Cancer Patients. <i>Clinical Nutrition</i> , 2019, 38, S140.	5.0	0
83	Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. <i>Cancer Medicine</i> , 2019, 8, 6923-6932.	2.8	67
84	CNO1: Whey Protein Isolate Supplementation Improves Body Composition, Muscle Strength and Treatment Tolerance in Malnourished Advanced Cancer Patients Undergoing Chemotherapy. <i>Clinical Nutrition</i> , 2019, 38, S1.	5.0	1
85	Fasting in oncology: a word of caution. <i>Nature Reviews Cancer</i> , 2019, 19, 177-177.	28.4	23
86	The institution of a Multi-disciplinary Italian Breast Unit: Reflections of the first psychosocial research study results on distress and quality of life. <i>Breast Journal</i> , 2019, 25, 678-681.	1.0	4
87	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 39-51.	4.4	11
88	Primary mediastinal germ cell tumors. <i>Seminars in Oncology</i> , 2019, 46, 107-111.	2.2	49
89	Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Induces Intracellular Ca ²⁺ Release through the Two-Pore Channel TPC1 in Metastatic Colorectal Cancer Cells. <i>Cancers</i> , 2019, 11, 542.	3.7	41
90	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218

#	ARTICLE	IF	CITATIONS
91	Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1165-1179.	7.3	48
92	Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. <i>Supportive Care in Cancer</i> , 2019, 27, 2425-2434.	2.2	34
93	Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk. <i>Supportive Care in Cancer</i> , 2019, 27, 2497-2506.	2.2	38
94	Reply to: Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO). <i>Supportive Care in Cancer</i> , 2019, 27, 1589-1590.	2.2	0
95	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. <i>Bone Marrow Transplantation</i> , 2019, 54, 867-876.	2.4	8
96	Lung Cancer App (LuCAApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. <i>BMJ Open</i> , 2019, 9, e025483.	1.9	22
97	The evolving landscape of human papillomavirus-related oropharyngeal squamous cell carcinoma at a single institution in Northern Italy. <i>Acta Otorhinolaryngologica Italica</i> , 2019, 39, 9-17.	1.5	15
98	Correlation between <i>NDRG1</i> gene polymorphism and neuropathy (N) in metastatic breast cancer (MBC) patients (pts) enrolled in the PAINTER study (Polymorphism And INcidence of Toxicity in ERibulin) <i>Tj ETQq0 0.0 rgBT /Qverlock 10</i>	0.6	0
99	Validation of a new prognostic body composition parameter in cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11597-11597.	1.6	0
100	Effect of whey protein isolate supplementation on body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11598-11598.	1.6	0
101	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	125
102	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2018, 53, 722-728.	2.4	5
103	In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status. <i>Journal of Immunotherapy</i> , 2018, 41, 190-200.	2.4	26
104	Update of the recommendations of the Italian Society of Medical Oncology on vaccination for seasonal influenza and pneumococcal infection in patients with cancer: Focus on prevention of pneumonia. <i>European Journal of Cancer Care</i> , 2018, 27, e12817.	1.5	5
105	Changes in food habits in cancer patients in Italy: a survey. <i>AIOM - SINPE - FAVO. Nutrition</i> , 2018, 55-56, 140-145.	2.4	16
106	Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 81-88.	0.6	104
107	Current use of clinical nutrition in oncology patients: Real world evidence from big data in Italy. <i>Annals of Oncology</i> , 2018, 29, viii618.	1.2	2
108	PCN327 - CHALLENGES AND OPPORTUNITIES IN CLINICAL NUTRITION IN ONCOLOGY: AVAILABLE EVIDENCE, REAL WORLD PRACTICES, AND THE WAY FORWARD. <i>Value in Health</i> , 2018, 21, S70.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). <i>Seminars in Oncology</i> , 2018, 45, 259-263.	2.2	2
110	T cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2018, 29, x11.	1.2	0
111	To fast, or not to fast before chemotherapy, that is the question. <i>BMC Cancer</i> , 2018, 18, 337.	2.6	37
112	Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk. <i>Clinical Nutrition</i> , 2018, 37, S14.	5.0	4
113	Stim and Orai mediate constitutive Ca ²⁺ entry and control endoplasmic reticulum Ca ²⁺ refilling in primary cultures of colorectal carcinoma cells. <i>Oncotarget</i> , 2018, 9, 31098-31119.	1.8	36
114	Breast and renal cancer-derived endothelial colony forming cells share a common gene signature. <i>European Journal of Cancer</i> , 2017, 77, 155-164.	2.8	19
115	An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. <i>Supportive Care in Cancer</i> , 2017, 25, 2823-2832.	2.2	7
116	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	2.8	38
117	Author response to commentary re. "Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey". <i>Nutrition</i> , 2017, 39-40, 97-98.	2.4	0
118	The integrating nutritional therapy in oncology (INTO) project: rationale, structure and preliminary results. <i>ESMO Open</i> , 2017, 2, e000221.	4.5	7
119	Nutritional support for cancer patients: still a neglected right?. <i>Supportive Care in Cancer</i> , 2017, 25, 3001-3004.	2.2	42
120	Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). <i>ESMO Open</i> , 2017, 2, e000167.	4.5	27
121	Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies. <i>Medical Oncology</i> , 2017, 34, 133.	2.5	4
122	Position paper on management of iron deficiency in adult cancer patients. <i>Expert Review of Hematology</i> , 2017, 10, 685-695.	2.2	15
123	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 163-167.	1.9	3
124	Multimodal Approach of Pulmonary Artery Intimal Sarcoma: A Single-Institution Experience. <i>Sarcoma</i> , 2017, 2017, 1-6.	1.3	31
125	Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database. <i>Bone Marrow Transplantation</i> , 2017, 52, 1218-1220.	2.4	4
126	Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 10098-10098.	1.6	3

#	ARTICLE	IF	CITATIONS
127	Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4549-4549.	1.6	0
128	Nutritional Support in Cancer Patients: A Position Paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE). <i>Journal of Cancer</i> , 2016, 7, 131-135.	2.5	98
129	Detection of Active Epstein-Barr Virus Infection in Duodenal Mucosa of Patients With Refractory Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1216-1220.	4.4	18
130	Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey. <i>Nutrition</i> , 2016, 32, 1028-1032.	2.4	69
131	Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. <i>European Journal of Cancer</i> , 2016, 65, 61-68.	2.8	130
132	c.428T>C (p.V143A) homozygous mutation in TP53 gene as a possible mechanism of resistance to trastuzumab therapy in gastric cancer. <i>Acta Oncologica</i> , 2016, 55, 1373-1375.	1.8	3
133	Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. <i>European Journal of Cancer</i> , 2016, 69, 110-118.	2.8	121
134	Simultaneous detection of circulating immunological parameters and tumor biomarkers in early stage breast cancer patients during adjuvant chemotherapy. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 211-228.	4.4	7
135	High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 475-481.	2.0	7
136	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 384-390.	2.4	7
137	Is allogeneic transplant for solid tumors still alive?. <i>Bone Marrow Transplantation</i> , 2016, 51, 751-752.	2.4	9
138	Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy. <i>Current Medicinal Chemistry</i> , 2016, 23, 3450-3480.	2.4	55
139	Diffusion of biosimilar hemopoietic growth factors use in oncology practice: an Italian experience. <i>Pharmacoeconomics Italian Research Articles</i> , 2015, 17, 1.	0.2	0
140	Results From a Time and Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease From Italian Sites. <i>Value in Health</i> , 2015, 18, A485-A486.	0.3	1
141	Treatment of pulmonary artery sarcoma (PAS): a single center experience. <i>Annals of Oncology</i> , 2015, 26, vi31.	1.2	0
142	Diffusion of biosimilar hemopoietic growth factors use in oncology practice. <i>Annals of Oncology</i> , 2015, 26, vi120.	1.2	0
143	Phase Angle and Handgrip Strength Are Sensitive Early Markers of Energy Intake in Hypophagic, Non-Surgical Patients at Nutritional Risk, with Contraindications to Enteral Nutrition. <i>Nutrients</i> , 2015, 7, 1828-1840.	4.1	26
144	Meningeal Melanomatosis: A Challenge for Timely Diagnosis. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	9

#	ARTICLE	IF	CITATIONS
145	Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 689-702.	2.4	10
146	Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 195-211.	3.1	2
147	Renal effects of targeted anticancer therapies. <i>Nature Reviews Nephrology</i> , 2015, 11, 354-370.	9.6	95
148	Identification of transcriptionally active HPV infection in formalin-fixed, paraffin-embedded biopsies of oropharyngeal carcinoma. <i>Human Pathology</i> , 2015, 46, 681-689.	2.0	18
149	High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 70-75.	2.1	13
150	Breast cancer circulating biomarkers: advantages, drawbacks, and new insights. <i>Tumor Biology</i> , 2015, 36, 6653-6665.	1.8	38
151	High-dose chemotherapy for germ cell tumors: do we have a model?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 33-44.	3.1	15
152	Markers of squamocolumnar junction cells in normal tonsils and oropharyngeal cancer with and without HPV infection. <i>Histology and Histopathology</i> , 2015, 30, 833-9.	0.7	16
153	Impact of response to induction chemotherapy (CT) and prior paclitaxel (TXL)-based CT on the outcome of salvage high-dose chemotherapy (HDCT) for relapsed germ-cell tumors (GCT) in the modern era: An EBMT Solid Tumors Working Party study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4535-4535.	1.6	0
154	Conventional-dose (CDCT) versus high-dose chemotherapy (HDCT) in the salvage management of relapsed pure seminoma: Results from an international database.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15559-e15559.	1.6	0
155	In Vitro Efficient Expansion of Tumor Cells Deriving from Different Types of Human Tumor Samples. <i>Medical Sciences (Basel, Switzerland)</i> , 2014, 2, 70-81.	2.9	9
156	Store-Operated Ca ²⁺ Entry Does Not Control Proliferation in Primary Cultures of Human Metastatic Renal Cellular Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-19.	1.9	51
157	Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM). <i>Annals of Oncology</i> , 2014, 25, 1243-1247.	1.2	28
158	Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 501-506.	2.0	7
159	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.	1.9	3
160	An eight-colour flow cytometric method for the detection of reference values of lymphocyte subsets in selected healthy donors. <i>Clinical and Experimental Medicine</i> , 2014, 14, 249-259.	3.6	11
161	Systematic analysis of human oncogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates. <i>Infectious Agents and Cancer</i> , 2014, 9, 18.	2.6	34
162	Evaluation of Interaction Between NK Cells and Colorectal Carcinoma Cells for Development of NK Cell-Based Immunotherapy in Patients with Refractory Disease. <i>Blood</i> , 2014, 124, 5810-5810.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Analysis of the contemporary use of high-dose chemotherapy (HDCT) in germ cell tumors (GCT) in Europe: Early findings of an ongoing EBMT-sponsored study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15536-e15536.	1.6	1
164	Iron Supplementation Adjunct to Erythropoiesis Stimulating Agents Is Cost Saving for Chemotherapy-Related Anemia in the Era of Biosimilars. <i>Blood</i> , 2014, 124, 2165-2165.	1.4	0
165	Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. <i>Annals of Hematology</i> , 2013, 92, 1133-1134.	1.8	2
166	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. <i>Bone Marrow Transplantation</i> , 2013, 48, 414-418.	2.4	16
167	Autologous stem cell transplantation: is it still relevant in breast cancer?. <i>Breast Cancer Management</i> , 2013, 2, 447-450.	0.2	0
168	Case Report: Long-Lasting Response in a Patient with Metastatic Renal Cell Cancer Receiving Antitumor Cytotoxic T Lymphocytes. <i>Tumori</i> , 2013, 99, e282-e284.	1.1	1
169	Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e74402.	2.5	56
170	A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in <i>E. coli</i> . <i>PLoS ONE</i> , 2013, 8, e76022.	2.5	20
171	Case report: long-lasting response in a patient with metastatic renal cell cancer receiving antitumor cytotoxic T lymphocytes. <i>Tumori</i> , 2013, 99, 282e-4e.	1.1	0
172	Intensified chemotherapy with stem-cell rescue in germ-cell tumors. <i>Annals of Oncology</i> , 2012, 23, 815-822.	1.2	21
173	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. <i>Annals of Oncology</i> , 2012, 23, 435-441.	1.2	55
174	Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1505-1515.	3.1	14
175	Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. <i>Cytotherapy</i> , 2012, 14, 80-90.	0.7	29
176	An overview of viral oncology in Italy - report from the Pavia meeting on solid tumors. <i>Infectious Agents and Cancer</i> , 2012, 7, 23.	2.6	1
177	Store-Operated Ca ²⁺ Entry Is Remodelled and Controls In Vitro Angiogenesis in Endothelial Progenitor Cells Isolated from Tumoral Patients. <i>PLoS ONE</i> , 2012, 7, e42541.	2.5	121
178	Is adoptive T-cell therapy for solid tumors coming of age?. <i>Bone Marrow Transplantation</i> , 2012, 47, 1013-1019.	2.4	15
179	6146 POSTER Preclinical Study of Adoptive Immunotherapy With Natural Killer Cells in Combination With Anti-EGFR Monoclonal Antibodies and Cytokines in Metastatic Colorectal Cancer. <i>European Journal of Cancer</i> , 2011, 47, S436.	2.8	0
180	Percutaneous Vertebral Augmentation in Metastatic Disease: State of the Art. <i>The Journal of Supportive Oncology</i> , 2011, 9, 4-10.	2.3	36

#	ARTICLE	IF	CITATIONS
181	Immunotherapeutic Intervention against Sarcomas. <i>Journal of Cancer</i> , 2011, 2, 350-356.	2.5	6
182	T Cell Therapy for Nasopharyngeal Carcinoma. <i>Journal of Cancer</i> , 2011, 2, 341-346.	2.5	26
183	Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?. <i>Journal of Cancer</i> , 2011, 2, 333-338.	2.5	39
184	Surgery Followed by Radiotherapy for the Treatment of Metastatic Epidural Spinal Cord Compression From Breast Cancer. <i>Spine</i> , 2011, 36, E1352-E1359.	2.0	13
185	Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report. <i>Current Drug Safety</i> , 2011, 6, 275-276.	0.6	7
186	Vascular Endothelial Growth Factor Stimulates Endothelial Colony Forming Cells Proliferation and Tubulogenesis by Inducing Oscillations in Intracellular Ca ²⁺ Concentration. <i>Stem Cells</i> , 2011, 29, 1898-1907.	3.2	140
187	Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. <i>Immunotherapy</i> , 2011, 3, 487-490.	2.0	3
188	Fulvestrant for advanced male breast cancer patients: a case series. <i>Annals of Oncology</i> , 2011, 22, 985.	1.2	13
189	High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3214-3223.	1.6	89
190	Multimodal Approach to the Management of Metastatic Epidural Spinal Cord Compression (MESCC) Due to Solid Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1467-1473.	0.8	21
191	Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2010, 28, 10025-10025.	1.6	6
192	Cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2509-2509.	1.6	0
193	Re: 'A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small-Cell Lung Cancer: A Randomized Trial'. <i>Journal of the National Cancer Institute</i> , 2009, 101, 67-67.	6.3	0
194	Response: Re: 'A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small-Cell Lung Cancer: A Randomized Trial'. <i>Journal of the National Cancer Institute</i> , 2009, 101, 67-68.	6.3	0
195	Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. <i>Cancer</i> , 2009, 115, 1169-1173.	4.1	13
196	Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. <i>Pediatric Blood and Cancer</i> , 2009, 52, 767-771.	1.5	144
197	Imaging in nasopharyngeal carcinoma: the value of 18-Fluorine Fluorodeoxyglucose PET/CT in comparison to conventional imaging modalities CT and MRI. <i>Radiology and Oncology</i> , 2009, 43, .	1.7	2
198	Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 131-133.	2.4	5

#	ARTICLE	IF	CITATIONS
199	Are metastatic testicular tumors curable with high-dose chemotherapy and stem-cell rescue?. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 126-127.	4.3	0
200	Iron Supplementation during Treatment with Erythropoiesis-Stimulating Agents for Cancer-Related Anemia. <i>Chemotherapy</i> , 2008, 54, 417-420.	1.6	3
201	Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbeoetin Alfa. <i>Journal of Clinical Oncology</i> , 2008, 26, 1619-1625.	1.6	161
202	Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 256-267.	4.3	78
203	Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry. <i>Journal of Clinical Oncology</i> , 2008, 26, 592-592.	1.6	8
204	High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Support for Solid Tumors in Adults. <i>Seminars in Hematology</i> , 2007, 44, 286-295.	3.4	13
205	GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. <i>Cytotherapy</i> , 2007, 9, 499-507.	0.7	19
206	Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2007, 92, 418-420.	3.5	15
207	High-dose sequential chemotherapy (HDSC) with peripheral blood progenitor cells (PBPC) support for high-risk breast cancer (BC). <i>Journal of Clinical Oncology</i> , 2007, 25, 11026-11026.	1.6	0
208	Darbeoetin alpha coming of age. <i>Anticancer Research</i> , 2007, 27, 4419-24.	1.1	0
209	European experience of allogeneic hematopoietic stem cell transplantation for metastatic renal carcinoma: On behalf of the french ITAC group and the EBMT Solid Tumour Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 21.	2.0	0
210	Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. <i>British Journal of Cancer</i> , 2006, 94, 1016-1020.	6.4	39
211	Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. <i>Future Oncology</i> , 2006, 2, 667-676.	2.4	1
212	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. <i>Annals of Oncology</i> , 2006, 17, 1134-1140.	1.2	84
213	High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. <i>Annals of Oncology</i> , 2006, 17, 1479-1488.	1.2	39
214	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. <i>Cancer</i> , 2005, 104, 2099-2103.	4.1	50
215	Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virusâ€“Targeted Cytotoxic T Lymphocytes. <i>Journal of Clinical Oncology</i> , 2005, 23, 8942-8949.	1.6	265
216	Incidence of Human Cytomegalovirus Infection in Patients with Refractory Solid Tumors Receiving Nonmyeloablative Allogeneic Stem Cell Transplants versus Recipients of Standard SCT for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 423-428.	2.0	5

#	ARTICLE	IF	CITATIONS
217	Survival of adults treated for medulloblastoma using paediatric protocols. <i>European Journal of Cancer</i> , 2005, 41, 1304-1310.	2.8	56
218	Autologous EBV-specific cytotoxic T lymphocytes for the treatment of EBV-related nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 2512-2512.	1.6	0
219	Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2004, 15, 113-117.	1.2	79
220	Iron Supplement in Cancer Patients Receiving Erythropoietin. <i>Journal of Clinical Oncology</i> , 2004, 22, 4428-4428.	1.6	1
221	Evidence of graft-versus-tumour effect following allogeneic haematopoietic stem cell transplantation in renal cancer other than clear cell type. <i>Bone Marrow Transplantation</i> , 2004, 34, 917-918.	2.4	1
222	Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. <i>International Journal of Cancer</i> , 2004, 110, 76-86.	5.1	23
223	High Dose Chemotherapy and Hematopoietic Progenitor Cell Transplantation for Breast Cancer. <i>Journal of Chemotherapy</i> , 2004, 16, 108-111.	1.5	2
224	Prognostic factors for survival in renal cell cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMT Solid Tumours Working Party. <i>Journal of Clinical Oncology</i> , 2004, 22, 6666-6666.	1.6	0
225	Prognostic factors for survival in renal cell cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMT Solid Tumours Working Party. <i>Journal of Clinical Oncology</i> , 2004, 22, 6666-6666.	1.6	0
226	Optimising management of neutropenia and anaemia in cancer chemotherapy—advances in cytokine therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, S39-S47.	4.4	18
227	Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999. <i>Bone Marrow Transplantation</i> , 2003, 32, 489-494.	2.4	52
228	Randomized, Controlled, Multicenter Phase III Trial of Standard-Dose Fluorouracil-Epirubicin-Cyclophosphamide (FEC), Compared with Time-Intensive FEC (FEC-G) and Mitoxantrone-Methotrexate-Mitomycin C (MMM-G) in Metastatic Breast Carcinoma. <i>Journal of Chemotherapy</i> , 2003, 15, 184-191.	1.5	13
229	Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. <i>Annals of Oncology</i> , 2003, 14, 1177-1184.	1.2	21
230	Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen. <i>Cancer</i> , 2002, 94, 2409-2415.	4.1	120
231	Correspondence. <i>Clinical Oncology</i> , 2002, 14, 82.	1.4	3
232	Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen. <i>Cancer</i> , 2002, 94, 2409-2415.	4.1	5
233	Costs of autologous stem-cell transplantation in solid tumours. <i>Annals of Oncology</i> , 2001, 12, 131.	1.2	1
234	Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell transplantation as a therapeutic option for breast cancer. <i>Haematologica</i> , 2001, 86, 900-7.	3.5	4

#	ARTICLE	IF	CITATIONS
235	Pulmonary function and complications following chemotherapy and stem cell support in breast cancer. <i>European Respiratory Journal</i> , 2000, 15, 56-61.	6.7	7
236	Negative immunomagnetic purging of peripheral blood stem cell harvests from breast carcinoma patients reduces tumor cell contamination while not affecting hematopoietic recovery. <i>Cancer</i> , 2000, 88, 2758-2765.	4.1	6
237	Transfusion of platelet concentrates cryopreserved with ThromboSol plus low-dose dimethylsulphoxide in patients with severe thrombocytopenia: a pilot study. <i>British Journal of Haematology</i> , 2000, 108, 653-659.	2.5	26
238	Optimal CD34+ Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2000, 18, 3319-3320.	1.6	18
239	Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 1360-1377.	1.6	296
240	Re: Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1271-1272.	6.3	2
241	Minimal tumor contamination of hematopoietic harvests from breast cancer patients can be easily detected by liquid culture assay. <i>Cytotherapy</i> , 2000, 2, 39-44.	0.7	0
242	Mitomycin C as an alternative to irradiation to inhibit the feeder layer growth in long-term culture assays. <i>Cytotherapy</i> , 2000, 2, 281-286.	0.7	58
243	Pulmonary function and complications following chemotherapy and stem cell support in breast cancer. <i>European Respiratory Journal</i> , 2000, 15, 56.	6.7	2
244	Somatic mutations at the T-cell antigen receptor in antineoplastic drug-exposed populations: comparison with sister chromatid exchange frequency. <i>International Archives of Occupational and Environmental Health</i> , 1999, 72, 315-322.	2.3	22
245	Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma. , 1999, 85, 2295-2296.		2
246	Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment. <i>Anticancer Research</i> , 1999, 19, 2373-6.	1.1	2
247	Efficacy of epirubicin/paclitaxel combination in mobilizing large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen. <i>Haematologica</i> , 1999, 84, 924-9.	3.5	6
248	Epithelial tumour cell detection and the unsolved problems of nested RT-PCR: a new sensitive one step method without false positive results. <i>Bone Marrow Transplantation</i> , 1998, 22, 693-698.	2.4	29
249	Autologous Platelet Collection and Storage to Support Thrombocytopenia in Patients Undergoing High-Dose Chemotherapy and Circulating Progenitor Cell Transplantation for High-Risk Breast Cancer. <i>Vox Sanguinis</i> , 1998, 75, 224-229.	1.5	10
250	High-dose chemotherapy and stem-cell support in breast cancer. <i>Lancet, The</i> , 1998, 352, 1220.	18.7	0
251	Progression from Nodular to Lymphangitic Subcutaneous Metastasis from Clear Cell Endometrial Carcinoma: Ct Findings. <i>Tumori</i> , 1998, 84, 387-390.	1.1	4
252	Autologous Platelet Collection and Storage to Support Thrombocytopenia in Patients Undergoing High-Dose Chemotherapy and Circulating Progenitor Cell Transplantation for–High-Risk Breast Cancer. <i>Vox Sanguinis</i> , 1998, 75, 224-229.	1.5	1

#	ARTICLE	IF	CITATIONS
253	Autologous platelet transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell transplantation for stage II/III breast cancer. <i>Haematologica</i> , 1998, 83, 718-23.	3.5	5
254	Megakaryocytic Progenitors Can Be Generated Ex Vivo and Safely Administered to Autologous Peripheral Blood Progenitor Cell Transplant Recipients. <i>Blood</i> , 1997, 89, 2679-2688.	1.4	177
255	A new "two step" procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 615-619.	2.4	19
256	Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. <i>Bone Marrow Transplantation</i> , 1997, 20, 167-169.	2.4	17
257	Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. <i>British Journal of Cancer</i> , 1997, 75, 1368-1372.	6.4	23
258	Circulating progenitor cell collection: experience from 275 leukaphereses in various malignancies and in healthy donors. <i>Haematologica</i> , 1996, 81, 208-15.	3.5	7
259	Juvenile chronic myelogenous leukemia: In vitro characterization before and after allogeneic bone marrow transplantation. <i>Medical and Pediatric Oncology</i> , 1995, 24, 166-170.	1.0	2
260	Splenic metastases in patients with portal hypertension. <i>European Journal of Cancer</i> , 1995, 31, 1885-1886.	2.8	2
261	Dose Intensification of Chemotherapy in Advanced Breast Cancer: A Feasibility Phase II Study. <i>Tumori</i> , 1994, 80, 273-275.	1.1	1
262	Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3 on Small Cell Lung Cancer Cells. <i>Cancer Investigation</i> , 1994, 12, 283-288.	1.3	8
263	Sustained remission of immune-mediated red cell aplasia in a child after intravenous administration of gamma globulin. <i>Journal of Pediatrics</i> , 1994, 125, 403-405.	1.8	1
264	Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. <i>Bone Marrow Transplantation</i> , 1994, 13, 403-10.	2.4	35
265	Successful bone marrow transplantation in children with severe aplastic anemia using HLA-partially matched family donors. <i>American Journal of Hematology</i> , 1993, 42, 328-333.	4.1	8
266	Toxic Epidermal Necrolysis Following <i>Yersinia enterocolitica</i> Infection. <i>International Journal of Dermatology</i> , 1993, 32, 75-75.	1.0	4
267	Myeloprotective effect of medroxyprogesterone acetate (MPA). <i>European Journal of Cancer</i> , 1993, 29, 1073.	2.8	2
268	Late onset of gallbladder carcinoma with meningeal carcinomatosis. <i>European Journal of Cancer</i> , 1992, 28, 1589.	2.8	6
269	Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1992, 80, 545-549.	2.5	12
270	Evaluation of the Effect of Medroxyprogesterone Acetate on Bone Marrow Progenitor Cells. <i>Tumori</i> , 1991, 77, 399-402.	1.1	3

#	ARTICLE	IF	CITATIONS
271	Establishment and characterization of a B-cell line derived from a patient with a myelodysplastic syndrome which expresses myelomonocytic and lymphoid markers. <i>British Journal of Haematology</i> , 1991, 78, 167-172.	2.5	11
272	Postgraduate training in Italy. <i>Lancet</i> , The, 1990, 336, 56.	13.7	2
273	Effects of recombinant human H-subunit and L-subunit ferritins on in vitro growth of human granulocyte-monocyte progenitors. <i>British Journal of Haematology</i> , 1988, 68, 367-372.	2.5	15
274	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM,) <i>Tj ETQq0 0 0 rgBT1/0verlock210 Tf 50 6</i>	1.4	51
275	Recombinant gamma-interferon induces in vitro monocytic differentiation of blast cells from patients with acute nonlymphocytic leukemia and myelodysplastic syndromes. <i>Leukemia</i> , 1988, 2, 55-9.	7.2	9
276	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM,) <i>Tj ETQq0 0 0 rgBT1/0verlock210 Tf 50 6</i>	1.4	51
277	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 1987, 70, 1014-1019.	1.4	78
278	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , 1987, 70, 1014-1019.	1.4	3
279	Implementation of a learning factory for research, education and training: the SUPSI Mini-Factory. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
280	Creating a Methodology to Train Manufacturing SMEs: The Lift Europe Case. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
281	Lycopene Reduces Skin Toxicity in Patients Treated with Panitumumab-Containing Therapy for Metastatic Colorectal Cancer – A Randomized Double-Blind Placebo-Controlled Pilot Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0